G‐CSF administration prior to donor lymphocyte apheresis promotes anti‐leukaemic effects in allogeneic HCT patients
Autor: | Simona Jahnke, Irmtraud Schober-Melms, Wolfgang Bethge, Dominik Schneidawind, Rupert Handgretinger, Christoph Faul, Michael Schumm, Lothar Kanz, Corina Schneidawind |
---|---|
Rok vydání: | 2019 |
Předmět: |
Adult
Male Adolescent Lymphocyte Graft vs Host Disease Graft vs Leukemia Effect Donor lymphocyte infusion 03 medical and health sciences 0302 clinical medicine Risk Factors Granulocyte Colony-Stimulating Factor medicine Humans Transplantation Homologous Cumulative incidence Retrospective Studies business.industry Hematopoietic Stem Cell Transplantation Hematology Middle Aged medicine.disease Donor Lymphocytes Survival Analysis Granulocyte colony-stimulating factor medicine.anatomical_structure Apheresis Graft-versus-host disease Lymphocyte Transfusion 030220 oncology & carcinogenesis Immunology Female Stem cell business 030215 immunology |
Zdroj: | British Journal of Haematology. 186:60-71 |
ISSN: | 1365-2141 0007-1048 |
DOI: | 10.1111/bjh.15881 |
Popis: | Donor lymphocyte infusion (DLI) is an effective method to establish full donor chimerism or to prevent and treat relapse after allogeneic haematopoietic cell transplantation (allo-HCT). Usually, DLIs are collected from naive donors as steady-state lymphocytes. When donor lymphocytes are collected during stem cell apheresis, donors are pre-treated with granulocyte colony-stimulating factor (G-CSF). However, the impact of G-CSF stimulation and the resulting composition of DLIs on beneficial anti-leukaemic responses and survival remain elusive. Therefore, we performed a retrospective analysis to evaluate the role of G-CSF-DLIs: 44 patients received either steady-state DLIs or G-CSF-DLIs to prevent and treat relapse or establish full donor chimerism after allo-HCT. The G-CSF-DLI patient cohort showed an improved conversion to full donor chimerism and a lower cumulative incidence of relapse or disease progression without a significantly increased cumulative incidence of graft-versus-host disease (GVHD). CD34+ cells, monocytic myeloid-derived suppressor cells and monocytes as well as donor age and the subsequent occurrence of chronic GVHD were identified as risk factors that significantly improve overall survival after DLI administration. In conclusion, our data suggest that administration of G-CSF-DLIs results in graft-versus-leukaemia effects without exacerbating GVHD, therefore, improving survival after DLIs. |
Databáze: | OpenAIRE |
Externí odkaz: |